LEONARD JOHN M
SEC CIK 1563584 · EDGAR
BoughtSold
Most active insiders at NTLA, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | LEONARD JOHN M | Pres, CEO, Dir | — | $1.44M |
| 2 | Cohen Fred E | Dir | $1.40M | — |
| 3 | Dulac Edward J III | EVP, CFO | — | $234.2K |
| 4 | BASTA JAMES | EVP, GC | — | $112.4K |
| 5 | Lebwohl David | EVP, Chief Medical Off | — | $109.6K |
| 6 | Dube Michael P | VP, CAO | — | $104.4K |
| 7 | Clark Eliana | EVP, Chief Technical Off | — | $96.0K |
| 8 | Schultes Birgit C | EVP, CSO | — | $78.9K |
| 9 | Bhanji Muna | Dir | — | — |
| 10 | Keresty Georgia | Dir | — | — |
Transactions 28
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MT | 2026-08-24 16:05 | 2026-08-20+ | NTLA | Intellia Therapeutics, Inc. | LEONARD JOHN M | Pres, CEO, Dir | S - Sale | $12.65 | -22.7K | 1.15M | -2% | -$286.8K |
| 2026-04-27 17:03 | 2026-04-23 | IQV | IQVIA | LEONARD JOHN M | Dir | A - Grant | $0.00 | +1,571 | 16.9K | +10% | $0 | |
| D | 2026-03-03 | 2026-03-01 | NTLA | Intellia Therapeutics, Inc. | LEONARD JOHN M | Pres, CEO, Dir | A - Grant | $0.00 | +156.4K | 1.17M | +15% | $0 |
| 2026-01-07 | 2026-01-05 | NTLA | Intellia Therapeutics, Inc. | LEONARD JOHN M | Pres, CEO, Dir | S - Sale | $9.21 | -34.1K | 1.01M | -3% | -$314.5K | |
| DMT | 2025-12-12 | 2025-12-11+ | NTLA | Intellia Therapeutics, Inc. | LEONARD JOHN M | Pres, CEO, Dir | M - OptEx | $6.83 | +58.5K | 1.05M | +6% | +$399.7K |
| DMT | 2025-12-12 | 2025-12-11 | NTLA | Intellia Therapeutics, Inc. | LEONARD JOHN M | Pres, CEO, Dir | S - Sale+OE | $9.49 | -88.1K | 1.08M | -8% | -$836.4K |
| 2025-04-25 | 2025-04-24 | IQV | IQVIA | LEONARD JOHN M | Dir | A - Grant | $0.00 | +1,592 | 15.4K | +12% | $0 | |
| D | 2025-03-04 | 2025-03-01 | NTLA | Intellia Therapeutics, Inc. | LEONARD JOHN M | Pres, CEO, Dir | A - Grant | $0.00 | +136.0K | 1.08M | +14% | $0 |
| 2025-01-07 | 2025-01-03 | NTLA | Intellia Therapeutics, Inc. | LEONARD JOHN M | Pres, CEO, Dir | S - Sale | $12.18 | -26.8K | 941.1K | -3% | -$326.5K | |
| D | 2025-01-03 | 2025-01-01 | NTLA | Intellia Therapeutics, Inc. | LEONARD JOHN M | Pres, CEO, Dir | M - OptEx | — | +7,850 | 967.9K | +0.8% | — |
| 2024-05-09 | 2024-05-07 | IQV | IQVIA | LEONARD JOHN M | Dir | A - Grant | $0.00 | +1,047 | 13.8K | +8% | $0 | |
| D | 2024-03-05 | 2024-03-01 | NTLA | Intellia Therapeutics, Inc. | LEONARD JOHN M | Pres, CEO, Dir | A - Grant | $0.00 | +113.6K | 960.1K | +13% | $0 |
| 2024-01-05 | 2024-01-03 | NTLA | Intellia Therapeutics, Inc. | LEONARD JOHN M | Pres, CEO, Dir | S - Sale | $29.46 | -19.2K | 846.5K | -2% | -$566.3K | |
| D | 2024-01-03 | 2024-01-01 | NTLA | Intellia Therapeutics, Inc. | LEONARD JOHN M | Pres, CEO, Dir | M - OptEx | — | +7,848 | 865.7K | +0.9% | — |
| 2023-05-12 | 2023-05-10 | IQV | IQVIA | LEONARD JOHN M | Dir | A - Grant | $0.00 | +1,063 | 12.7K | +9% | $0 | |
| D | 2023-03-03 | 2023-03-01 | NTLA | Intellia Therapeutics, Inc. | LEONARD JOHN M | Pres, CEO, Dir | A - Grant | $0.00 | +91.0K | 857.9K | +12% | $0 |
| 2023-01-06 | 2023-01-04 | NTLA | Intellia Therapeutics, Inc. | LEONARD JOHN M | Pres, CEO, Dir | S - Sale | $37.21 | -6,673 | 766.8K | -0.9% | -$248.3K | |
| D | 2023-01-04 | 2023-01-01 | NTLA | Intellia Therapeutics, Inc. | LEONARD JOHN M | Pres, CEO, Dir | M - OptEx | — | +7,848 | 773.5K | +1% | — |
| 2022-05-13 | 2022-05-11 | IQV | IQVIA | LEONARD JOHN M | Dir | A - Grant | $0.00 | +995 | 11.7K | +9% | $0 | |
| D | 2022-03-04 | 2022-01-01 | NTLA | Intellia Therapeutics, Inc. | LEONARD JOHN M | Pres, CEO, Dir | M - OptEx | — | +7,848 | 727.2K | +1% | — |
| D | 2022-03-04 | 2022-03-01 | NTLA | Intellia Therapeutics, Inc. | LEONARD JOHN M | Pres, CEO, Dir | A - Grant | $0.00 | +41.0K | 765.6K | +6% | $0 |
| D | 2022-03-04 | 2022-01-01 | NTLA | Intellia Therapeutics, Inc. | LEONARD JOHN M | Pres, CEO, Dir | S - Sale+OE | $112.26 | -2,493 | 724.7K | -0.3% | -$279.9K |
| DM | 2021-09-01 | 2021-08-30+ | NTLA | Intellia Therapeutics, Inc. | LEONARD JOHN M | Pres, CEO, Dir | M - OptEx | $17.06 | +121.4K | 758.1K | +19% | +$2.07M |
| DM | 2021-09-01 | 2021-08-30+ | NTLA | Intellia Therapeutics, Inc. | LEONARD JOHN M | Pres, CEO, Dir | S - Sale+OE | $160.83 | -121.4K | 719.3K | -14% | -$19.52M |
| DM | 2021-08-25 | 2021-08-23 | NTLA | Intellia Therapeutics, Inc. | LEONARD JOHN M | Pres, CEO, Dir | S - Sale+OE | $152.01 | -27.1K | 727.6K | -4% | -$4.13M |
| D | 2021-08-25 | 2021-08-23 | NTLA | Intellia Therapeutics, Inc. | LEONARD JOHN M | Pres, CEO, Dir | M - OptEx | $13.40 | +27.1K | 746.4K | +4% | +$363.7K |
| DM | 2021-08-20 | 2021-08-19 | NTLA | Intellia Therapeutics, Inc. | LEONARD JOHN M | Pres, CEO, Dir | S - Sale+OE | $151.28 | -22.7K | 719.3K | -3% | -$3.43M |
| D | 2021-08-20 | 2021-08-19 | NTLA | Intellia Therapeutics, Inc. | LEONARD JOHN M | Pres, CEO, Dir | M - OptEx | $13.40 | +22.7K | 742.0K | +3% | +$303.9K |
Purchase Sale Sale after option exercise All abbreviations